Ford Motor Company vs Sana Biotechnology Inc — how do they compare? Ford Motor Company trades at $14.11 (market cap $56.50B), while Sana Biotechnology Inc trades at $3.21 (market cap $987.94M). The key difference: Ford Motor Company is far larger — about 57.2× Sana Biotechnology Inc's market cap, and Ford Motor Company pays a 4.23% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| F | SANA | |
|---|---|---|
Market Cap | $56.50B | $987.94M |
Sector | Consumer Cyclical | Health |
52-Week High | $17.44 | $5.92 |
52-Week Low | $10.82 | $2.68 |
Enterprise Value | $185.53B | $962.13M |
Dividend Yield | 4.23% | — |
Signals from Pluang's Aura AI — not financial advice
Ford (F) trades at $14.09, up 1.15% today, with a bullish technical signal from moving averages and a consensus analyst price target of $15.00. Recent earnings show volatility with Q1 2026 beating expectations but Q4 2025 missing, while revenue grew to $187.27 billion in 2025. The company maintains strong cash flow from operations at $21.28 billion and announced a $0.15 dividend for H1 2026, though net income was negative at -$8.18 billion due to high costs.
Ford's outlook is mixed, with opportunities from EV expansion and labor stability, but risks include profit margin pressure and rising debt. Analysts are cautiously optimistic with 34% buy ratings, yet investors should weigh competitive threats and macroeconomic headwinds against the stock's low P/E of 11.84 and dividend yield.
Sana Biotechnology (SANA) trades at $3.225, down 9.66% on the day, reflecting market volatility despite a bullish technical signal and strong analyst support. The company shows significant financial losses with a -$244.17M net income for 2025 and negative cash flows, but has beaten earnings expectations in two of the last three quarters. Recent news highlights clinical progress in cell therapies and a $69M capital raise via an ATM facility in May 2026.
The investment case balances high-risk fundamentals against promising clinical developments and overwhelming analyst optimism. While substantial losses and cash burn present clear risks, the company's scientific advancements and 82% buy rating from analysts suggest potential long-term upside for risk-tolerant investors in the biotech sector.
Trailing returns across standard periods
Latest headlines on both assets
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →